Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole on Patients With Chronic Periodontitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the clinical and microbiological effectiveness of the moxifloxacin compared with the combination ciprofloxacin - metronidazole, when used as adjunctive therapy to scaling and root planning for the treatment of advanced chronic periodontitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis

NCT02125812

Aggressive Periodontitis

COMPLETED PHASE4

The Response of Pathogens to the Respective or Combined Treatment of SRP and Local Minocycline in Chronic Periodontitis

NCT02355977

Chronic Periodontitis

COMPLETED PHASE4

Alternative Antibiotic Regime in the Treatment of GAgP

NCT02223702

Generalized Aggressive Periodontitis Aggressive Periodontitis

COMPLETED PHASE4

Amoxicillin and Metronidazole in Association With Non-surgical Therapy in Aggressive Periodontitis Treatment

NCT03933501

Generalized Aggressive Periodontitis

COMPLETED PHASE4

Impact of Non-surgical Periodontal Therapy on Oral and Gut Microbiome

NCT04580355

Microbial Colonization Periodontal Diseases Periodontal Inflammation

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Periodontitis is an endemic inflammatory disease caused by a mixed bacterial biofilm infection that is followed by destruction of tooth supporting tissues. Standard of care consists of lifelong mechanical removal of the biofilm. However, outcome is variable. According to recent EFP and AAP reviews, adjunctive antimicrobial therapy may be beneficial.However, bearing in mind that Colombia has reported the frequent presence of Enterobacteriaceae (Klebsiella and Enterobacter) in subgingival plaque of patients with chronic periodontitis, the response to treatment may be different.The enteric have shown resistance to amoxicillin, amoxicillin / clavulanate, metronidazole and tetracycline in studies conducted in the United States, Norway, Brazil and Colombia.Although the combination ciprofloxacin metronidazole has been recommended in the dental literature are not known publications that demonstrate its effectiveness against periodontopathogens and enteric present in subgingival plaque of subjects with chronic periodontitis.On the other hand, some in vitro studies have demonstrated the effectiveness of moxifloxacin against periodontopathogens, but was not aware of any clinical trials or in vitro studies on antibiotic resistance and susceptibility to enteric isolated subgingival plaque of patients with chronic periodontitis in which employs moxifloxacin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moxifloxacin

Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.

Group Type EXPERIMENTAL

moxifloxacin

Intervention Type DRUG

400 mg moxifloxacin once daily for 7 days

Ciprofloxacin plus metronidazole

Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days

Group Type ACTIVE_COMPARATOR

Ciprofloxacin plus metronidazole

Intervention Type DRUG

Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

moxifloxacin

400 mg moxifloxacin once daily for 7 days

Intervention Type DRUG

Ciprofloxacin plus metronidazole

Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Moxifloxacin hydrochloride ciprofloxacino metronidazole benzoato

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age and up
* clinical and radiographic signs of severe (CAL 5 mm or more) chronic periodontitis.
* at least 20 natural teeth in situ
* pocket probing depths (PPDs) of ≥ 5 mm at a minimum of eight tooth sites
* willingness to participate and to be available at all times required for participation
* over 30% of the teeth present must have a PPDs)≥ 4 mm and insertion loss ≥ 5 mm evaluated by an experienced periodontist
* informed consent signed by the patient

Exclusion Criteria

* if they (or parents or siblings) show confirmed or assumed allergies or hyper-sensitive skin reactions against moxifloxacin, ciprofloxacin (or other quinolones as listed in the "summary of product characteristics, Version Juli 2005"), metronidazole (or other 5-nitroimidazoles and ingredients of Flagyl® 400mg as listed in the "summary of product characteristics, Version Juli 2007"), systemic diseases or conditions as listed in the above mentioned "summary of product characteristics"
* subjects who have undergone antibiotic therapy three months before the start of the study under interrogation
* have Down's syndrome
* known AIDS/HIV
* regularly take systemic medication affecting the periodontal conditions, e.g. phenytoin, nifedipine, and/or steroid drugs
* professional periodontal therapy during 6 months prior to baseline
* require antibiotic treatment for dental appointments
* are pregnant or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No